Decision Diagnostics 

$0.000100
7
+$0.00+0% Monday 20:00

統計

當日最高
0.0001
當日最低
0.0001
52週高點
0.0001
52週低點
0.0001
成交量
2,000,000
平均成交量
0
市值
35,787.1
本益比
-
股息殖利率
-
股息
-

財報

30Nov預期
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
-0
-0
-0
0
預期EPS
0
實際EPS
0

財務

-1,499.19%利潤率
未盈利
2015
2016
2017
2018
2019
2020
1.98M營收
-29.67M淨利

其他人也在關注

此清單是根據在 Stock Events 上追蹤 DECN 的使用者自選建立的。這不是投資建議。

競爭對手

此清單為基於近期市場事件的分析。並非投資建議。

關於

Decision Diagnostics Corp. (DECN), founded in 2000 and based in Westlake Village, California, specializes in developing electronic medical record (EMR) technologies primarily optimized for smartphones. The company provides a wide array of offerings, including both regulated and unregulated diagnostic solutions, as well as home-use testing products for individuals managing chronic illnesses. They also facilitate direct-to-patient logistics for diabetes programs and concentrate on creating mobile-centric e-health products and associated technological innovations. A key part of their product line involves glucose monitoring. This includes the GenUltimate! glucose test strips, classified as a Class II medical device for personal at-home human use. For animal health, they manufacture PetSure! glucose test strips, designed to measure glucose levels in dogs and cats and compatible with legacy Zoetis AlphaTrak glucometers. Additionally, they offer the proprietary GenUltimate! 4Pets Glucose system, which combines the GenUltimate! 4Pets strip with the Avantage meter, enabling glucose testing for canine, feline, and equine patients. Further glucose strip options include GenUltimate! Sure and GenUltimate! Precis. Beyond product development, Decision Diagnostics actively acquires and maintains a portfolio of intellectual property, spanning patents, trademarks, and specialized manufacturing equipment. Their software solutions include MD@Hand, a comprehensive management system for both inpatient and outpatient care; Practice Probe, a data mining utility designed to extract information from physician practice management systems; and ResidenceWare, a residential management system that streamlines communication between commercial or residential real estate managers and their tenants through networked applications. Ultimately, their EMR innovations provide crucial tools for physicians directly at the point of patient care. The company was originally known as InstaCare Corp. before officially changing its name to Decision Diagnostics Corp. in November 2011.
Show more...
執行長
Mr. Keith M. Berman
員工
6
國家
美國
ISIN
US2434431084

上市

0 Comments

分享你的想法

FAQ

Decision Diagnostics 今天的股價是多少?
DECN 目前價格為 $0.00 USD,過去 24 小時上漲了 +0%。在圖表上更密切關注 Decision Diagnostics 股價表現。
Decision Diagnostics 的股票代號是什麼?
根據交易所不同,股票代號可能會有所差異。例如,在 OTC Link 交易所,Decision Diagnostics 的股票以代號 DECN 進行交易。
Decision Diagnostics 的股價在上漲嗎?
DECN 股票較上週上漲 +0%,本月上漲 +0%,過去一年 Decision Diagnostics 上漲 +0%。
Decision Diagnostics 的市值是多少?
今天 Decision Diagnostics 的市值為 35,787.1
Decision Diagnostics 上一季度的財報如何?
DECN 上一季度的財報為每股 0 USD,預估為 0 USD,帶來 +非數值% 的驚喜。下一季度的預估財報為每股 不適用 USD。
Decision Diagnostics 去年的營收是多少?
Decision Diagnostics 去年的營收為 1.98MUSD。
Decision Diagnostics 去年的淨利是多少?
DECN 去年的淨收益為 -29.67MUSD。
Decision Diagnostics 有多少名員工?
截至 July 10, 2026,公司共有 6 名員工。
Decision Diagnostics 位於哪個產業?
Decision Diagnostics從事於Health & Wellness產業。
Decision Diagnostics 何時完成拆股?
Decision Diagnostics 最近沒有進行任何拆股。
Decision Diagnostics 的總部在哪裡?
Decision Diagnostics 的總部位於 美國 的 Westlake Village。